SLC2A1 and Dravet syndrome: Some syndromes seemed to respond particularly well: bothchildren with AHC, who completed the trial, had ≥50% reduction in seizures/paroxysmalevents; one child with GLUT1-DS and gait difficulties, but without current seizures,became free of paroxysmal events.